Korro Bio, Inc. (KRRO) stock
KRRONasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.61−0.70 (-4.89%)
Close on Nov 13, 2026Market cap $200.42MP/E –Yield –
Korro Bio r&d expenses
Research and development expenses are spending on new products and technology.
Korro Bio's R&D Expenses for the twelve months ending Sep 30, 2026 was $50.52M, down 28.5% year over year. For fiscal 2025 it was $65.58M, up 3.0% from the year before. The highest annual figure on record is $65.58M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.58M | +3.0% |
| FY2024 | Dec 31, 2024 | $63.64M | +11.2% |
| FY2023 | Dec 31, 2023 | $57.25M | +35.7% |
| FY2022 | Dec 31, 2022 | $42.20M | -30.7% |
| FY2021 | Dec 31, 2021 | $60.92M | +62.8% |
| FY2020 | Dec 31, 2020 | $37.42M | +99.2% |
| FY2019 | Dec 31, 2019 | $18.78M | +58.1% |
| FY2018 | Dec 31, 2018 | $11.88M | -0.7% |
| FY2017 | Dec 31, 2017 | $11.97M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $12.10M | -12.4% |
| Q2 FY2026 | Jun 30, 2026 | $13.59M | -32.5% |
| Q1 FY2026 | Mar 31, 2026 | $12.95M | -34.4% |
| Q4 FY2025 | Dec 31, 2025 | $11.88M | -30.0% |
| Q3 FY2025 | Sep 30, 2025 | $13.82M | -13.4% |
| Q2 FY2025 | Jun 30, 2025 | $20.14M | +17.5% |
| Q1 FY2025 | Mar 31, 2025 | $19.74M | +45.4% |
| Q4 FY2024 | Dec 31, 2024 | $16.96M | +10.0% |
| Q3 FY2024 | Sep 30, 2024 | $15.96M | +14.0% |
| Q2 FY2024 | Jun 30, 2024 | $17.14M | +30.6% |
| Q1 FY2024 | Mar 31, 2024 | $13.57M | -7.6% |
| Q4 FY2023 | Dec 31, 2023 | $15.42M | +349.4% |
| Q3 FY2023 | Sep 30, 2023 | $14.01M | +19.6% |
| Q2 FY2023 | Jun 30, 2023 | $13.13M | -1.1% |
| Q1 FY2023 | Mar 31, 2023 | $14.69M | +6.6% |
| Q4 FY2022 | Dec 31, 2022 | $3.43M | -73.1% |
| Q3 FY2022 | Sep 30, 2022 | $11.72M | -25.2% |
| Q2 FY2022 | Jun 30, 2022 | $13.27M | -23.7% |
| Q1 FY2022 | Mar 31, 2022 | $13.78M | -8.8% |
| Q4 FY2021 | Dec 31, 2021 | $12.75M | +7.8% |
| Q3 FY2021 | Sep 30, 2021 | $15.66M | +54.3% |
| Q2 FY2021 | Jun 30, 2021 | $17.40M | +98.6% |
| Q1 FY2021 | Mar 31, 2021 | $15.11M | +126.5% |
| Q4 FY2020 | Dec 31, 2020 | $11.83M | +90.9% |
| Q3 FY2020 | Sep 30, 2020 | $10.15M | +94.5% |
| Q2 FY2020 | Jun 30, 2020 | $8.76M | +123.5% |
| Q1 FY2020 | Mar 31, 2020 | $6.67M | +93.6% |
| Q4 FY2019 | Dec 31, 2019 | $6.20M | +112.1% |
| Q3 FY2019 | Sep 30, 2019 | $5.22M | +47.1% |
| Q2 FY2019 | Jun 30, 2019 | $3.92M | – |
| Q1 FY2019 | Mar 31, 2019 | $3.45M | – |
| Q4 FY2018 | Dec 31, 2018 | $2.92M | – |
| Q3 FY2018 | Sep 30, 2018 | $3.55M | – |
See a number that looks wrong?